BDBM312379 3-[3-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]-thiophen-2-ylcarbamoyl]-bicyclo[2.2.2]oct-2-ene-2-carboxylic acid::US9604977, Example 125

SMILES: OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCCc2c1-c1nc(no1)C1CC1

InChI Key: InChIKey=HRKNKRRDJMTWRP-UHFFFAOYSA-N

Data: 2 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 312379   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Fatty acid-binding protein 5 (FABP5) (Homo sapiens (Human))	BDBM312379 (3-[3-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-5,6,7,8...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCCc2c1-c1nc(no1)C1CC1 |t:3,(1.72,-4.41,;3.26,-4.41,;4.03,-5.74,;4.03,-3.07,;3.26,-1.74,;4.03,-.41,;5.57,-.41,;6.34,-1.74,;5.57,-3.07,;4.23,-2.3,;5.36,-1.18,;1.72,-1.74,;.95,-3.07,;.95,-.41,;-.59,-.41,;-1.5,-1.65,;-2.96,-1.18,;-4.17,-2.14,;-5.67,-1.79,;-6.34,-.41,;-5.67,.98,;-4.17,1.32,;-2.96,.36,;-1.5,.84,;-.73,2.17,;.81,2.17,;1.29,3.64,;.04,4.54,;-1.2,3.64,;2.62,4.41,;4.16,4.41,;3.39,5.74,)| Show InChI InChI=1S/C24H27N3O4S/c28-21(17-12-6-8-13(9-7-12)18(17)24(29)30)26-23-19(15-4-2-1-3-5-16(15)32-23)22-25-20(27-31-22)14-10-11-14/h12-14H,1-11H2,(H,26,28)(H,29,30)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	50	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair
Fatty acid-binding protein 4 (FABP4) (Homo sapiens (Human))	BDBM312379 (3-[3-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-5,6,7,8...) Show SMILES OC(=O)C1=C(C2CCC1CC2)C(=O)Nc1sc2CCCCCc2c1-c1nc(no1)C1CC1 |t:3,(1.72,-4.41,;3.26,-4.41,;4.03,-5.74,;4.03,-3.07,;3.26,-1.74,;4.03,-.41,;5.57,-.41,;6.34,-1.74,;5.57,-3.07,;4.23,-2.3,;5.36,-1.18,;1.72,-1.74,;.95,-3.07,;.95,-.41,;-.59,-.41,;-1.5,-1.65,;-2.96,-1.18,;-4.17,-2.14,;-5.67,-1.79,;-6.34,-.41,;-5.67,.98,;-4.17,1.32,;-2.96,.36,;-1.5,.84,;-.73,2.17,;.81,2.17,;1.29,3.64,;.04,4.54,;-1.2,3.64,;2.62,4.41,;4.16,4.41,;3.39,5.74,)| Show InChI InChI=1S/C24H27N3O4S/c28-21(17-12-6-8-13(9-7-12)18(17)24(29)30)26-23-19(15-4-2-1-3-5-16(15)32-23)22-25-20(27-31-22)14-10-11-14/h12-14H,1-11H2,(H,26,28)(H,29,30)	PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	20	n/a	n/a	n/a	n/a	n/a	n/a
Hoffman-La Roche Inc. US Patent					Assay Description Compounds were profiled for activity against human FABP4 (huFABP4) and/or human FABP5 (huFABP5) in Terbium (Tb) time resolved-fluorescence energy tra...				US Patent US9604977 (2017) BindingDB Entry DOI: 10.7270/Q2FX7CJB
					More data for this Ligand-Target Pair